tradingkey.logo

FDA Grants Orphan Drug Designation By NS Pharma To Ns-229 For Treatment Of Eosinophilic Granulomatosis With Polyangiitis

ReutersApr 21, 2025 11:23 AM

- Nippon Shinyaku Co Ltd 4516.T:

  • NS PHARMA: FDA GRANTS ORPHAN DRUG DESIGNATION TO NS-229 FOR TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI